{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T15:36:22Z","timestamp":1777217782151,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018998","name":"Ege University Research Foundation","doi-asserted-by":"crossref","award":["22969"],"award-info":[{"award-number":["22969"]}],"id":[{"id":"10.13039\/501100018998","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018998","name":"Ege University Research Foundation","doi-asserted-by":"crossref","award":["22969"],"award-info":[{"award-number":["22969"]}],"id":[{"id":"10.13039\/501100018998","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NLRP1 is predominantly overexpressed in breast cancer tissue, and the evaluated activation of NLRP1 inflammasome is associated with tumor growth, angiogenesis, and metastasis. Therefore, targeting NLRP1 activation could be a crucial strategy in anticancer therapy. In this study, we investigated the hypothesis that NLRP1 pathway may contribute to the cytotoxic effects of celecoxib and nimesulide in MDA-MB-231 cells. First of all, IC<jats:sub>50<\/jats:sub> values and inhibitory effects on the colony-forming ability of drugs were evaluated in cells. Then, the alterations in the expression levels of NLRP1 inflammasome components induced by drugs were investigated. Subsequently, the release of inflammatory cytokine IL-1\u03b2 and the activity of caspase-1 in drug-treated cells were measured. According to our results, celecoxib and nimesulide selectively inhibited the viability of MDA-MB-231 cells. These drugs remarkably inhibited the colony-forming ability of cells. The expression levels of NLRP1 inflammasome components decreased in celecoxib-treated cells, accompanied by decreased caspase-1 activity and IL-1\u03b2 release. In contrast, nimesulide treatment led to the upregulation of the related protein expressions with unchanged caspase-1 activity and increased IL-1\u03b2 secretion. Our results indicated that the NLRP1 inflammasome pathway might contribute to the antiproliferative effects of celecoxib in MDA-MB-231 cells but is not a crucial mechanism for nimesulide.<\/jats:p>","DOI":"10.1007\/s00210-024-03286-2","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:01:56Z","timestamp":1720702916000},"page":"9191-9202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells"],"prefix":"10.1007","volume":"397","author":[{"given":"Ege","family":"Arzuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dervi\u015f","family":"Birim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcliz","family":"Arma\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/ijo.2015.3075","volume":"47","author":"MD Alle","year":"2015","unstructured":"Alle MD, Jones LJ (2015) The role of inflammation in the progression of breast cancer: friend or foe? (Review). Int J Oncol 47:797\u2013805. https:\/\/doi.org\/10.3892\/ijo.2015.3075","journal-title":"Int J Oncol"},{"key":"3286_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","volume":"20","author":"V Ashok","year":"2011","unstructured":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66\u201370. https:\/\/doi.org\/10.1016\/j.breast.2010.07.004","journal-title":"Breast"},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"R422","DOI":"10.1186\/bcr1019","volume":"7","author":"GD Basu","year":"2005","unstructured":"Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7:R422\u2013R435. https:\/\/doi.org\/10.1186\/bcr1019","journal-title":"Breast Cancer Res"},{"key":"3286_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1517\/14656566.1.2.277","volume":"1","author":"A Bennett","year":"2000","unstructured":"Bennett A, Villa G (2000) Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother 1:277\u2013286. https:\/\/doi.org\/10.1517\/14656566.1.2.277","journal-title":"Expert Opin Pharmacother"},{"key":"3286_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11010-010-0682-4","volume":"350","author":"C Bocca","year":"2011","unstructured":"Bocca C, Bozzo F, Bassignana A, Miglietta A (2011) Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 350:59\u201370. https:\/\/doi.org\/10.1007\/s11010-010-0682-4","journal-title":"Mol Cell Biochem"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10552-011-9832-6","volume":"22","author":"JL Bosco","year":"2011","unstructured":"Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L (2011) Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 22:1553\u20131561. https:\/\/doi.org\/10.1007\/s10552-011-9832-6","journal-title":"Cancer Causes Control"},{"key":"3286_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/abio.1976.9999","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254. https:\/\/doi.org\/10.1006\/abio.1976.9999","journal-title":"Anal Biochem"},{"key":"3286_CR8","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/bcr3409","volume":"15","author":"RD Brand\u00e3o","year":"2013","unstructured":"Brand\u00e3o RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS (2013) A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15:R29. https:\/\/doi.org\/10.1186\/bcr3409","journal-title":"Breast Cancer Res"},{"key":"3286_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492\u20132502. https:\/\/doi.org\/10.1001\/jama.295.21.2492","journal-title":"JAMA"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.bcp.2009.03.015","volume":"77","author":"B Chen","year":"2009","unstructured":"Chen B, Su B, Chen S (2009) A COX-2 inhibitor nimesulide analogue selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. Biochem Pharmacol 77:1787\u20131794. https:\/\/doi.org\/10.1016\/j.bcp.2009.03.015","journal-title":"Biochem Pharmacol"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.clinthera.2014.06.015","volume":"36","author":"J Chen","year":"2014","unstructured":"Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L (2014) Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther 36:1253\u20131263","journal-title":"Clin Ther"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3892\/ol.2020.11284","volume":"19","author":"M Ci\u0105\u017cy\u0144ska","year":"2020","unstructured":"Ci\u0105\u017cy\u0144ska M, Bednarski IA, W\u00f3dz K, Narbutt J, Lesiak A (2020) NLRP1 and NLRP3 inflammasomes as a new approach to skin carcinogenesis. Oncol Lett 19:1649\u20131656. https:\/\/doi.org\/10.3892\/ol.2020.11284","journal-title":"Oncol Lett"},{"key":"3286_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/jcp.55.6.429","volume":"55","author":"C Costa","year":"2002","unstructured":"Costa C, Soares R, Reis-Filho JS, Leit\u00e3o D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429\u2013434. https:\/\/doi.org\/10.1136\/jcp.55.6.429","journal-title":"J Clin Pathol"},{"key":"3286_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"M Coussens","year":"2002","unstructured":"Coussens M, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867. https:\/\/doi.org\/10.1038\/nature01322","journal-title":"Nature"},{"key":"3286_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2867-12-53","volume":"2","author":"ZJ Dai","year":"2012","unstructured":"Dai ZJ, Ma XB, Kang HF, Gao J, Min WL, Guan HT, Diao Y, Lu WF, Wang XJ (2012) Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 2:53. https:\/\/doi.org\/10.1186\/1475-2867-12-53","journal-title":"Cancer Cell Int"},{"key":"3286_CR16","doi-asserted-by":"publisher","first-page":"CD004233","DOI":"10.1002\/14651858.CD004233.pub4","volume":"2013","author":"S Derry","year":"2013","unstructured":"Derry S, Moore RA (2013) Single dose oral celecoxib for acute postoperative pain in adults. The Cochrane Database Syst Rev 2013:CD004233. https:\/\/doi.org\/10.1002\/14651858.CD004233.pub4","journal-title":"The Cochrane Database Syst Rev"},{"key":"3286_CR17","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1210\/jc.2004-2029","volume":"90","author":"ES D\u00edaz-Cruz","year":"2005","unstructured":"D\u00edaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Meta 90:2563\u20132570. https:\/\/doi.org\/10.1210\/jc.2004-2029","journal-title":"J Clin Endocrinol Meta"},{"key":"3286_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00006676-200301000-00007","volume":"26","author":"G Eibl","year":"2003","unstructured":"Eibl G, Reber HA, Wente MN, Hines OJ (2003) The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26:33\u201341. https:\/\/doi.org\/10.1097\/00006676-200301000-00007","journal-title":"Pancreas"},{"key":"3286_CR19","first-page":"2641","volume":"28","author":"S Elangovan","year":"2008","unstructured":"Elangovan S, Hsieh TC, Wu JM (2008) Growth inhibition of human MDA-MB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1\/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. Anticancer Res 28:2641\u20132647","journal-title":"Anticancer Res"},{"key":"3286_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-05-1603","volume":"12","author":"DM Elaraj","year":"2006","unstructured":"Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Alexander HR (2006) The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12:1088\u20131096. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1603","journal-title":"Clin Cancer Res"},{"key":"3286_CR21","doi-asserted-by":"publisher","first-page":"29034","DOI":"10.18632\/oncotarget.4732","volume":"6","author":"P Escobar","year":"2015","unstructured":"Escobar P, Bouclier C, Serret J, Bi\u00e8che I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Genevi\u00e8ve D, Molina F, Jorgensen C, Lazennec G (2015) IL-1\u03b2 produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget 6:29034\u201329047. https:\/\/doi.org\/10.18632\/oncotarget.4732","journal-title":"Oncotarget"},{"key":"3286_CR22","unstructured":"FDA (1998) Celebrex. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1998\/20998lbl.pdf Accessed 20 October 2023"},{"key":"3286_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","volume":"10","author":"L Franchi","year":"2009","unstructured":"Franchi L, Eigenbrod T, Mu\u00f1oz-Planillo R, Nu\u00f1ez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241\u2013247. https:\/\/doi.org\/10.1038\/ni.1703","journal-title":"Nat Immunol"},{"key":"3286_CR24","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI26321","volume":"115","author":"DR Green","year":"2005","unstructured":"Green DR, Kroemer G (2005) Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 115:2610\u20132617","journal-title":"J Clin Invest"},{"key":"3286_CR25","doi-asserted-by":"publisher","first-page":"36107","DOI":"10.1038\/srep36107","volume":"6","author":"B Guo","year":"2016","unstructured":"Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci Rep 6:36107. https:\/\/doi.org\/10.1038\/srep36107","journal-title":"Sci Rep"},{"key":"3286_CR26","first-page":"2006","volume":"6","author":"T Hida","year":"2000","unstructured":"Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6:2006\u20132011","journal-title":"Clin Cancer Res"},{"key":"3286_CR27","first-page":"831","volume":"3","author":"LG Howes","year":"2007","unstructured":"Howes LG (2007) Selective COX-2 inhibitors, NSAIDs and cardiovascular events-is celecoxib the safest choice? Ther Clin Risk Manag 3:831\u2013845","journal-title":"Ther Clin Risk Manag"},{"key":"3286_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/jcp.24815","volume":"230","author":"KF Hua","year":"2015","unstructured":"Hua KF, Chou JC, Ka SM, Tasi YL, Chen A, Wu SH, Chiu HW, Wong WT, Wang YF, Tsai CL, Ho CL, Lin CH (2015) Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1\u03b2 production. J Cell Physiol 230:863\u2013874. https:\/\/doi.org\/10.1002\/jcp.24815","journal-title":"J Cell Physiol"},{"key":"3286_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12935-014-0126-4","volume":"14","author":"T Jia","year":"2014","unstructured":"Jia T, Zhang L, Duan Y, Zhang M, Wang G, Zhang J, Zhao Z (2014) The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K\/Akt-SKP2-Cip\/Kips pathway. Cancer Cell Int 14:126. https:\/\/doi.org\/10.1186\/s12935-014-0126-4","journal-title":"Cancer Cell Int"},{"key":"3286_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fimmu.2017.01132","volume":"8","author":"M Kantono","year":"2017","unstructured":"Kantono M, Guo B (2017) Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol 8:1132. https:\/\/doi.org\/10.3389\/fimmu.2017.01132","journal-title":"Front Immunol"},{"key":"3286_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","volume":"19","author":"R Karki","year":"2019","unstructured":"Karki R, Kanneganti TD (2019) Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer 19:197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y","journal-title":"Nat Rev Cancer"},{"key":"3286_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1096\/fj.03-0473com","volume":"18","author":"T Kuwano","year":"2004","unstructured":"Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M (2004) Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18:300\u2013310. https:\/\/doi.org\/10.1096\/fj.03-0473com","journal-title":"FASEB J"},{"key":"3286_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. https:\/\/doi.org\/10.1155\/2014\/149185","journal-title":"J Immunol Res"},{"key":"3286_CR34","first-page":"1486","volume":"12","author":"S Lanza-Jacoby","year":"2003","unstructured":"Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH (2003) The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2\/neu mice. Cancer Epidemiol Biomarkers Prev 12:1486\u20131491","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3286_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3748\/wjg.v9.i5.915","volume":"9","author":"JY Li","year":"2003","unstructured":"Li JY, Wang XZ, Chen FL, Yu JP, Luo HS (2003) Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9:915\u2013920. https:\/\/doi.org\/10.3748\/wjg.v9.i5.915","journal-title":"World J Gastroenterol"},{"key":"3286_CR36","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.2147\/CMAR.S178567","volume":"10","author":"J Li","year":"2018","unstructured":"Li J, Hao Q, Cao W, Vadgama JV, Wu Y (2018) Celecoxib in breast cancer prevention and therapy. Cancer Manag Res 10:4653\u20134667. https:\/\/doi.org\/10.2147\/CMAR.S178567","journal-title":"Cancer Manag Res"},{"key":"3286_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.839041","volume":"10","author":"S Lillo","year":"2022","unstructured":"Lillo S, Saleh M (2022) Inflammasomes in cancer progression and anti-tumor immunity. Front Cell Dev Biol 10:839041. https:\/\/doi.org\/10.3389\/fcell.2022.839041","journal-title":"Front Cell Dev Biol"},{"key":"3286_CR38","doi-asserted-by":"publisher","first-page":"18563","DOI":"10.1074\/jbc.M010787200","volume":"276","author":"CH Liu","year":"2001","unstructured":"Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563\u201318569","journal-title":"J Biol Chem"},{"issue":"2","key":"3286_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","volume":"8","author":"V Masoud","year":"2017","unstructured":"Masoud V, Pag\u00e8s G (2017) Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 8(2):120\u2013134","journal-title":"World J Clin Oncol"},{"key":"3286_CR40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1349-7006.2000.tb01030.x","volume":"91","author":"S Nakatsugi","year":"2000","unstructured":"Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91:886\u2013892. https:\/\/doi.org\/10.1111\/j.1349-7006.2000.tb01030.x","journal-title":"Jpn J Cancer Res"},{"key":"3286_CR41","first-page":"769","volume":"12","author":"Y Pan","year":"2003","unstructured":"Pan Y, Zhang JS, Gazi MH, Young CY (2003) The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 12:769\u2013774","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3286_CR42","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/bcr2246","volume":"11","author":"JR Reed","year":"2009","unstructured":"Reed JR, Leon RP, Hall MK, Schwertfeger KL (2009) Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 11:R21. https:\/\/doi.org\/10.1186\/bcr2246","journal-title":"Breast Cancer Res"},{"key":"3286_CR43","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1078-0432.ccr-0902-03","volume":"10","author":"MS Shaik","year":"2004","unstructured":"Shaik MS, Chatterjee A, Singh M (2004) Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res 10:1521\u20131529. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0902-03","journal-title":"Clin Cancer Res"},{"key":"3286_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.trsl.2022.09.002","volume":"252","author":"BR Sharma","year":"2023","unstructured":"Sharma BR, Kanneganti TD (2023) Inflammasome signaling in colorectal cancer. Transl Res 252:45\u201352. https:\/\/doi.org\/10.1016\/j.trsl.2022.09.002","journal-title":"Transl Res"},{"key":"3286_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2407-11-130","volume":"11","author":"G Soria","year":"2011","unstructured":"Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A (2011) Inflammatory mediators in breast cancer: coordinated expression of TNF\u03b1 & IL-1\u03b2 with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130. https:\/\/doi.org\/10.1186\/1471-2407-11-130","journal-title":"BMC Cancer"},{"key":"3286_CR46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature10759","volume":"481","author":"T Strowig","year":"2012","unstructured":"Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature 481:278\u2013286. https:\/\/doi.org\/10.1038\/nature10759","journal-title":"Nature"},{"key":"3286_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/imr.12884","volume":"297","author":"CY Taabazuing","year":"2020","unstructured":"Taabazuing CY, Griswold AR, Bachovchin DA (2020) The NLRP1 and CARD8 inflammasomes. Immunol Rev 297:13\u201325. https:\/\/doi.org\/10.1111\/imr.12884","journal-title":"Immunol Rev"},{"key":"3286_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.15430\/JCP.2017.22.2.62","volume":"22","author":"H Thi","year":"2017","unstructured":"Thi H, Hong S (2017) Inflammasome as a therapeutic target for cancer prevention and treatment. J Cancer Prev 22:62\u201373. https:\/\/doi.org\/10.15430\/JCP.2017.22.2.62","journal-title":"J Cancer Prev"},{"key":"3286_CR49","doi-asserted-by":"publisher","first-page":"4938473","DOI":"10.1155\/2017\/4938473","volume":"2017","author":"Y Wei","year":"2017","unstructured":"Wei Y, Huang H, Qiu Z, Li H, Tan J, Ren G, Wang X (2017) NLRP1 overexpression is correlated with the tumorigenesis and proliferation of human breast tumor. Biomed Res Int 2017:4938473. https:\/\/doi.org\/10.1155\/2017\/4938473","journal-title":"Biomed Res Int"},{"key":"3286_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022544","volume":"99","author":"B Wen","year":"2020","unstructured":"Wen B, Wei YT, Mu LL, Wen GR, Zhao K (2020) The molecular mechanisms of celecoxib in tumor development. Medicine 99:e22544. https:\/\/doi.org\/10.1097\/MD.0000000000022544","journal-title":"Medicine"},{"key":"3286_CR51","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/bcr1864","volume":"10","author":"S Woditschka","year":"2008","unstructured":"Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN (2008) Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res 10:R18. https:\/\/doi.org\/10.1186\/bcr1864","journal-title":"Breast Cancer Res"},{"key":"3286_CR52","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1038\/onc.2017.26","volume":"36","author":"Z Zhai","year":"2017","unstructured":"Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, Fujita M (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820\u20133830. https:\/\/doi.org\/10.1038\/onc.2017.26","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1007\/s00210-024-03348-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000}}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03286-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:49:05Z","timestamp":1730191745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03286-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00210-024-03348-5","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00210-024-03348-5","URL":"https:\/\/doi.org\/10.1007\/s00210-024-03348-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}